dx 8951 has been researched along with camptothecin in 67 studies
| Studies (dx 8951) | Trials (dx 8951) | Recent Studies (post-2010) (dx 8951) | Studies (camptothecin) | Trials (camptothecin) | Recent Studies (post-2010) (camptothecin) |
|---|---|---|---|---|---|
| 73 | 18 | 15 | 13,002 | 2,229 | 5,391 |
| Protein | Taxonomy | dx 8951 (IC50) | camptothecin (IC50) |
|---|---|---|---|
| Histone deacetylase 3 | Homo sapiens (human) | 0.05 | |
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | 7.4 | |
| DNA topoisomerase 1 | Homo sapiens (human) | 1.9799 | |
| Somatostatin receptor type 1 | Homo sapiens (human) | 0.0022 | |
| Somatostatin receptor type 2 | Homo sapiens (human) | 0.0022 | |
| Somatostatin receptor type 4 | Homo sapiens (human) | 0.0022 | |
| Somatostatin receptor type 3 | Homo sapiens (human) | 0.0022 | |
| Somatostatin receptor type 5 | Homo sapiens (human) | 0.0022 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.97 | |
| Histone deacetylase 4 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 1 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 7 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 2 | Homo sapiens (human) | 0.05 | |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 11 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 8 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 6 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 9 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 5 | Homo sapiens (human) | 0.05 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (11.94) | 18.2507 |
| 2000's | 47 (70.15) | 29.6817 |
| 2010's | 7 (10.45) | 24.3611 |
| 2020's | 5 (7.46) | 2.80 |
| Authors | Studies |
|---|---|
| Jadhav, A; Kerns, E; Nguyen, K; Shah, P; Sun, H; Xu, X; Yan, Z; Yu, KR | 1 |
| Kabir, M; Kerns, E; Nguyen, K; Shah, P; Sun, H; Wang, Y; Xu, X; Yu, KR | 1 |
| Kabir, M; Kerns, E; Neyra, J; Nguyen, K; Nguyễn, ÐT; Shah, P; Siramshetty, VB; Southall, N; Williams, J; Xu, X; Yu, KR | 1 |
| Aonuma, M; Ejima, A; Hirota, Y; Kumazawa, E; Mitsui, I; Ohsuki, S; Sato, K; Sugimori, M; Terasawa, H; Uoto, K | 1 |
| Ishii, M; Joto, N; Kuga, H; Minami, M; Mitsui, I; Tohgo, A | 1 |
| Kono, A; Kumazawa, E; Shimazoe, T; Takiguchi, S; Tohgo, A | 1 |
| Saijo, N | 2 |
| Jimbo, T; Kumazawa, E; Ochi, Y; Tohgo, A | 1 |
| Ishida, T; Mori, M; Nishio, K; Nomoto, T; Saijo, N | 1 |
| Bigg, DC; Lavergne, O | 1 |
| Clark, GM; De Jager, RL; Izbicka, E; Lawrence, RA; Rowinsky, EK; Tohgo, A; Von Hoff, DD; Weitman, SD | 1 |
| Beran, M; Giles, FJ; Jeha, S; Kantarjian, H; Smith, TL; Vey, N | 1 |
| Nakaoka, M; Oguma, T; Ohshima, Y | 1 |
| Ejima, A; Imagawa, S; Ishii, M; Iwahana, M; Minami, M; Mitsui, I; Tohgo, A | 1 |
| Coyle, J; De Jager, RL; Drengler, R; Eckhardt, SG; Geyer, CE; Hammond, LA; Johnson, TR; Rizzo, J; Rowinsky, EK; Schwartz, G; Smetzer, L; Tolcher, A; Von Hoff, DD | 1 |
| Armand, JP; Boige, V; Ducreux, M; Faivre, S; Gatineau, M; Meely, K; Mekhaldi, S; Pautier, P; Raymond, E; Rixe, O | 1 |
| Boven, E; Hoogsteen, I; Pinedo, HM; Schlüper, HM; Van Hattum, AH | 1 |
| Cheverton, P; Coyle, J; De Jager, R; Ducharme, M; Sakamoto, N; Satomi, M; Suzuki, M; Tamanoi, K | 1 |
| Bevers, M; Kavanagh, JJ; Kudelka, AP; Levenback, C; Loyer, E; Verschraegen, CF; Vincent, M; Wolf, J | 1 |
| Inukai, K; Konno, T; Nakaoka, M; Oguma, T; Yamada, M | 1 |
| Coyle, J; De Jager, R; Ducharme, MP; Dumas, P; Hoff, PM; Lassere, Y; Lee, JJ; Pazdur, R; Royce, ME | 1 |
| Inaba, A; Konno, T; Nakaoka, M; Oguma, T | 1 |
| Coyle, J; De Jager, RL; Ducharme, MP; Hollywood, E; Ilson, D; Kelsen, D; Kemeny, N; Kleban, S; O'Reilly, E; Saltz, LB; Schwartz, GK; Sharma, S | 1 |
| Nishiyama, M; Okamoto, R; Okamura, T; Park, JS; Sekikawa, T; Sparreboom, A; Takano, H; Tanimoto, K; Verweij, J; Yamamoto, W | 1 |
| Inoue, K | 1 |
| Cortes, JE; De Jager, RL; Faderl, S; Garcia-Manero, G; Giles, FJ; Jeha, S; Kantarjian, HM; Thomas, DA | 1 |
| Boven, E; Erkelens, CA; Pinedo, HM; Schlüper, HM; Tohgo, A; van Hattum, AH | 1 |
| Boven, E; Hoogsteen, IJ; Kohlhagen, G; Maliepaard, M; Pinedo, HM; Pommier, Y; Scheffer, GL; Scheper, RJ; Schlüper, HM; van Hattum, AH | 1 |
| Bouvet, M; Hoffman, RM; Moossa, AR; Nassirpour, R; Sun, FX; Tohgo, A; Yagi, S | 1 |
| Bates, NP; Boven, E; Braybrooke, JP; Cheverton, PD; Dobbs, N; Pinedo, HM; Ruijter, R; Talbot, DC | 1 |
| Bailly, C; Lansiaux, A | 1 |
| Coyle, J; De Jager, RL; Ducharme, M; Figueroa, JA; Garrison, MA; Geyer, CE; Hammond, LA; Rowinsky, EK; Schwartz, G; Smetzer, L; Takimoto, CH; Tolcher, AW | 1 |
| Braybrooke, JP; Cheverton, P; Manegold, C; Mattson, K; Oyama, R; Ranson, M; Sekiguchi, M; Suzuki, M; Talbot, DC; Thatcher, N | 1 |
| Colucci, P; Cristofanilli, M; DeJager, R; Duggal, A; Esteva, FJ; Hortobagyi, GN; Rivera, E; Royce, M; Valero, V | 1 |
| Bastien, L; De Jager, R; Duggal, A; Hu, W; Kavanagh, JJ; Kudelka, AP; Loyer, E; Verschraegen, CF; Vincent, M | 1 |
| Coyle, J; DeJager, R; Hoff, PM; Pazdur, R; Rowinsky, EK; Royce, ME; Saltz, LB | 1 |
| Kumazawa, E; Ochi, Y | 1 |
| Masubuchi, N | 1 |
| Adams, M; Atkinson, R; Boven, E; Calvert, AH; Cervantes, A; Cheverton, P; Clamp, A; Ganesan, T; Jayson, GC; Lotz, J; Vasey, P | 1 |
| Atsumi, R; Masubuchi, N; May, RD | 1 |
| Atsumi, R; Iwasaki, D; Morikawa, H; Oguma, T | 1 |
| Kuga, H; Kumazawa, E; Ochi, Y; Shiose, Y | 1 |
| Alexander, J; Becker, RC; Bovill, E; Dyke, CK; Harrington, RA; Kunitada, S; Li, YF; Robertson, TL; Spencer, FA | 1 |
| Atsumi, R; Cicci, D; Gaudette, F; Gauthier-Dubois, G; Guilbaud, R; Oguma, T | 1 |
| Büchler, MW; Cheverton, P; Friess, H; Kleeff, J; Langman, S; Wanders, J; Wente, MN | 1 |
| Abou-Alfa, GK; Becerra, CR; De Jager, R; Eckhardt, SG; Feit, K; Kelsen, DP; O'Reilly, EM; Patt, YZ; Rowinsky, EK; Schwartz, GK; Sharma, S; Siegel, E | 1 |
| Ajani, JA; Baez, L; Becerra, CR; Cohn, A; De Jager, R; Feit, K; Kamida, M; Major, P; Silva, A; Takimoto, C | 1 |
| Richards, DA | 1 |
| Takimoto, CH | 1 |
| Chua, YJ; Cunningham, D | 1 |
| Abou-Alfa, GK; Ackerman, J; De Jager, RL; Eckhardt, SG; Feit, K; Harker, G; Hurwitz, H; Letourneau, R; Modiano, M; O'Reilly, EM; Tchekmedyian, NS | 1 |
| Owen, OG | 1 |
| Hashida, M; Kuga, H; Shiose, Y; Yamashita, F | 1 |
| Al Harbi, T; Al-Faris, N; Doyle, J; Gassas, A; Goia, C; Pappo, A | 1 |
| Bauer, S; Blay, JY; Christensen, TB; Daugaard, S; Hartmann, JT; Marreaud, S; Nielsen, OS; Pink, D; Reichardt, P; Schöffski, P; Van Glabbeke, M | 1 |
| Hashida, M; Kuga, H; Ochi, Y; Shiose, Y; Yamashita, F | 1 |
| Herzog, TJ; Wethington, SL; Wright, JD | 1 |
| Abe, Y; Ashida, S; Honda, T; Kasuya, Y; Masuda, T; Miyazaki, H; Morita, K; Naito, H; Nakada, T; Ogitani, Y; Yamaguchi, J; Yoshida, M | 1 |
| Li, XF; Liu, GF; Liu, L; Yu, SN; Zhang, SH | 1 |
| Agatsuma, T; Ishida, S; Ishii, C; Iwata, TN; Ogitani, Y; Wada, T | 1 |
| Doi, T; Hirotani, K; Kagari, T; Koga, Y; Koganemaru, S; Kojima, T; Kuboki, Y; Maeda, N; Matsumura, Y; Yamauchi, M; Yasunaga, M | 1 |
| Abe, M; Abe, Y; Agatsuma, T; Hashimoto, Y; Hayakawa, I; Hirotani, K; Iguchi, T; Ishizaka, T; Kagari, T; Kamai, Y; Kaneda, Y; Karibe, T; Koyama, K; Maeda, N; Morita, K; Murakami, M; Nakada, T; Nomura, T; Ogitani, Y; Shiose, Y; Ueno, S; Wakita, K; Zembutsu, A | 1 |
| Aida, T; Kai, K; Kishino, Y; Kumagai, K; Mori, K; Tsuchiya, Y | 1 |
| Agama, KK; Arakawa, Y; Bindra, RS; Choi, WS; Gayle, S; Jo, U; Jones, K; Murai, Y; Paralkar, V; Pommier, Y; Saha, LK; Sun, Y; Sundaram, RK; Van Doorn, J; Vasquez, JC; Yang, X | 1 |
| Gayle, S; Jones, K; Paradis, T; Paralkar, VM; Vasquez, J | 1 |
| Ashley, GW; Carreras, CW; Fontaine, SD; Reid, RR; Santi, DV | 1 |
9 review(s) available for dx 8951 and camptothecin
| Article | Year |
|---|---|
New chemotherapeutic agents for the treatment of non-small cell lung cancer: the Japanese experience.
Topics: Alkaloids; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbazoles; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Glucosides; Humans; Irinotecan; Japan; Lung Neoplasms; Mitomycin; Mitomycins; Neoplasms, Experimental; Paclitaxel; Purine Nucleosides; Staurosporine; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 1998 |
[The other camptothecins: recent advances with camptothecin analogues other than irinotecan and topotecan].
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Macromolecular Substances; Mice; Molecular Structure; Neoplasm Proteins; Prodrugs; Structure-Activity Relationship; Topoisomerase I Inhibitors | 1998 |
DX-8951f: summary of phase I clinical trials.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Humans | 2000 |
Preclinical and clinical trials of topoisomerase inhibitors.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Irinotecan; Lung Neoplasms; Topoisomerase I Inhibitors | 2000 |
[Drug delivery systems for cancer chemotherapy].
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Drug Delivery Systems; Drug Design; Humans; Lung Neoplasms; Particle Size | 2002 |
Chemotherapeutic gemcitabine doublets in pancreatic carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Survival Rate | 2005 |
Chemotherapy for advanced pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Organoplatinum Compounds; Palliative Care; Pancreatic Neoplasms; Pemetrexed; Taxoids; Topoisomerase I Inhibitors | 2006 |
Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma.
Topics: Antineoplastic Agents; Camptothecin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Neoplasm Recurrence, Local; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan | 2008 |
Efficacy of different chemotherapy regimens in treatment of advanced or metastatic pancreatic cancer: A network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Network Meta-Analysis; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2018 |
18 trial(s) available for dx 8951 and camptothecin
| Article | Year |
|---|---|
DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Thrombocytopenia; Vomiting | 2000 |
Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Topoisomerase I Inhibitors; Vomiting | 2000 |
Phase II study of intravenous DX-8951f in patients with advanced ovarian, tubal, or peritoneal cancer refractory to platinum, taxane, and topotecan.
Topics: Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Camptothecin; Drug Administration Schedule; Drug Resistance, Multiple; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum Compounds; Taxoids; Topotecan | 2000 |
Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): a novel camptothecin analog.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents; Camptothecin; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Thrombocytopenia | 2001 |
Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Leukopenia; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia; Topoisomerase I Inhibitors | 2001 |
Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Salvage Therapy; Stomatitis; Topoisomerase I Inhibitors | 2002 |
Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Topoisomerase I Inhibitors | 2003 |
A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Cohort Studies; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Models, Chemical; Neoplasms; Time Factors | 2003 |
Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Finland; Germany; Humans; Infusions, Intravenous; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Survival Analysis; Treatment Outcome; United Kingdom | 2003 |
A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Carcinoma; Disease Progression; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Survival Analysis; Treatment Outcome | 2003 |
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Camptothecin; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Taxoids; Topotecan | 2004 |
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patients with metastatic adenocarcinoma of the colon or rectum.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Female; Humans; Male; Middle Aged; Rectal Neoplasms | 2004 |
A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Taxoids; Topoisomerase I Inhibitors | 2004 |
DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors.
Topics: Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Delayed-Action Preparations; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Prodrugs; Tissue Distribution; Topoisomerase I Inhibitors | 2005 |
A Phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Area Under Curve; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Cholangiocarcinoma; Drug Administration Schedule; Female; Gallbladder Neoplasms; Half-Life; Humans; Male; Middle Aged; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome | 2005 |
A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Stomach Neoplasms; Treatment Outcome | 2005 |
Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2006 |
Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II--study of the EORTC Soft Tissue and Bone Sarcoma Group.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Leiomyosarcoma; Male; Middle Aged; Prospective Studies; Sarcoma, Synovial; Treatment Outcome | 2007 |
40 other study(ies) available for dx 8951 and camptothecin
| Article | Year |
|---|---|
Highly predictive and interpretable models for PAMPA permeability.
Topics: Artificial Intelligence; Caco-2 Cells; Cell Membrane Permeability; Humans; Models, Biological; Organic Chemicals; Regression Analysis; Support Vector Machine | 2017 |
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.
Topics: Drug Discovery; Organic Chemicals; Pharmaceutical Preparations; Solubility | 2019 |
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.
Topics: Animals; Computer Simulation; Databases, Factual; Drug Discovery; High-Throughput Screening Assays; Liver; Machine Learning; Male; Microsomes, Liver; National Center for Advancing Translational Sciences (U.S.); Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Rats; Rats, Sprague-Dawley; Retrospective Studies; United States | 2020 |
A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Camptothecin; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms; Solubility; Topoisomerase I Inhibitors; Transplantation, Heterologous; Tumor Cells, Cultured; Water | 1995 |
DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; DNA Topoisomerases, Type I; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Stability; Enzyme Inhibitors; Flow Cytometry; Humans; Irinotecan; Lung Neoplasms; Solubility; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured; Water | 1997 |
Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; DNA Fragmentation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Irinotecan; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasm Proteins; Neoplasm Transplantation; Pancreatic Neoplasms; Prodrugs; Splenic Neoplasms; Topoisomerase I Inhibitors; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured | 1997 |
Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Colonic Neoplasms; Humans; Irinotecan; Kidney Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Stomach Neoplasms; Subrenal Capsule Assay; Tumor Cells, Cultured | 1998 |
Characterization of a human small-cell lung cancer cell line resistant to a new water-soluble camptothecin derivative, DX-8951f.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Small Cell; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Lung Neoplasms; Solubility; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Water | 1998 |
Comparison of DX-8951f and topotecan effects on tumor colony formation from freshly explanted adult and pediatric human tumor cells.
Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Child; Dose-Response Relationship, Drug; Humans; Irinotecan; Neoplastic Stem Cells; Topotecan; Tumor Cells, Cultured | 1999 |
The topoisomerase I inhibitor DX-8951f is active in a severe combined immunodeficient mouse model of human acute myelogenous leukemia.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Humans; Leukemia, Myeloid, Acute; Mice; Mice, SCID; Survival Analysis; Time Factors; Topoisomerase I Inhibitors; Transplantation, Heterologous; Tumor Cells, Cultured | 2000 |
Sensitive high-performance liquid chromatographic method for the determination of the lactone form and the lactone plus hydroxy-acid forms of the new camptothecin derivative DX-8951 in human plasma using fluorescence detection.
Topics: Antineoplastic Agents, Phytogenic; Calibration; Camptothecin; Chromatography, High Pressure Liquid; Drug Stability; Humans; Hydroxy Acids; Indicators and Reagents; Lactones; Solutions; Spectrometry, Fluorescence | 2000 |
Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Camptothecin; Carcinoma, Small Cell; Cisplatin; DNA Primers; DNA Topoisomerases, Type I; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Stability; Fluorouracil; Glutathione; Glutathione S-Transferase pi; Glutathione Transferase; Humans; In Vitro Techniques; Inactivation, Metabolic; Isoenzymes; Lung Neoplasms; Neoplasm Proteins; Reverse Transcriptase Polymerase Chain Reaction; Topoisomerase I Inhibitors; Tubulin; Tubulin Modulators; Tumor Cells, Cultured | 2000 |
New analogues of camptothecins. Activity and resistance.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Colonic Neoplasms; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2000 |
High-Performance liquid chromatographic analysis of lactone and hydroxy acid of new antitumor drug, DX-8951 (exatecan), in mouse plasma.
Topics: Animals; Antineoplastic Agents; Calibration; Camptothecin; Chromatography, High Pressure Liquid; Hydroxy Acids; Lactones; Male; Mice; Mice, Inbred BALB C; Reproducibility of Results; Sensitivity and Specificity | 2001 |
Validation study of assay method for DX-8951 and its metabolite in human plasma and urine by high-performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry.
Topics: Antineoplastic Agents; Atmospheric Pressure; Calibration; Camptothecin; Chromatography, High Pressure Liquid; Humans; Mass Spectrometry; Sensitivity and Specificity | 2001 |
O(6)-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives.
Topics: Antineoplastic Agents, Phytogenic; Blotting, Western; Camptothecin; Drug Evaluation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Glutathione; Humans; Irinotecan; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Plasmids; RNA, Messenger; Topoisomerase I Inhibitors; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2002 |
The activity profile of the hexacyclic camptothecin derivative DX-8951f in experimental human colon cancer and ovarian cancer.
Topics: Animals; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cell Division; Cisplatin; Colonic Neoplasms; Disease Models, Animal; Female; Humans; Membrane Glycoproteins; Mice; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms, Experimental; Ovarian Neoplasms; Sulfhydryl Reagents; Tetraspanin 29; Tumor Cells, Cultured; Vault Ribonucleoprotein Particles; Xenograft Model Antitumor Assays | 2002 |
Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity.
Topics: Acridines; Animals; Antigens, CD; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Cell Division; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Female; Humans; Immunoenzyme Techniques; Isoquinolines; Membrane Glycoproteins; Mice; Mice, Nude; Mutation; Neoplasm Proteins; Neoplasms, Experimental; Ovarian Neoplasms; Tetrahydroisoquinolines; Tetraspanin 29; Tetrazolium Salts; Thiazoles; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2002 |
Efficacy of camptothecin analog DX-8951f (Exatecan Mesylate) on human pancreatic cancer in an orthotopic metastatic model.
Topics: Animals; Camptothecin; Deoxycytidine; Disease Models, Animal; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Pancreatic Neoplasms; Tumor Cells, Cultured | 2003 |
[A symphony for the camptothecins].
Topics: Antineoplastic Agents; Camptothecin; Enzyme Inhibitors; Irinotecan; Music; Neoplasms; Organosilicon Compounds; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topotecan | 2003 |
DE-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f: potent antitumor activities in various murine tumor models.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Male; Mice; Neoplasms, Experimental | 2004 |
Pharmacokinetics of DE-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f, in tumor-bearing mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Drug Carriers; Fibrosarcoma; Half-Life; Injections, Intravenous; Mice; Mice, Inbred BALB C; Neoplasm Transplantation | 2004 |
A predictive model of human myelotoxicity using five camptothecin derivatives and the in vitro colony-forming unit granulocyte/macrophage assay.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bone Marrow Cells; Camptothecin; Colony-Forming Units Assay; Dogs; Granulocyte Precursor Cells; Granulocytes; Humans; Inhibitory Concentration 50; Irinotecan; Macrophages; Maximum Tolerated Dose; Mice; Models, Biological | 2004 |
Validation study of a method for assaying DE-310, a macromolecular carrier conjugate containing an anti-tumor camptothecin derivative, and the free drug in tumor tissue by high performance liquid chromatography/atmospheric pressure chemical ionization tan
Topics: Animals; Atmospheric Pressure; Camptothecin; Chromatography, High Pressure Liquid; Drug Carriers; Drug Stability; Fibrosarcoma; Freezing; Male; Mass Spectrometry; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Reproducibility of Results; Sensitivity and Specificity | 2005 |
A possible mechanism for the long-lasting antitumor effect of the macromolecular conjugate DE-310: mediation by cellular uptake and drug release of its active camptothecin analog DX-8951.
Topics: Animals; Antineoplastic Agents; Ascites; Camptothecin; Chromatography, High Pressure Liquid; Endocytosis; Fibrosarcoma; Fluorescence; Injections, Intraperitoneal; Lysosomes; Macrophages; Mice; Microscopy, Confocal; Neoplasm Transplantation; Tumor Cells, Cultured | 2005 |
Combined coagulation phase-directed factor Xa inhibition with heparin compounds and DX-9065a - a direct and selective antagonist.
Topics: Anticoagulants; Blood Coagulation Tests; Calcium Chloride; Camptothecin; Drug Synergism; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Heparin; Heparin, Low-Molecular-Weight; Humans; Sensitivity and Specificity | 2004 |
Validation study of a method for assaying DE-310, a macromolecular carrier conjugate containing an anti-tumor camptothecin derivative, and the free drug in human plasma by HPLC and LC/MS/MS.
Topics: Antineoplastic Agents; Camptothecin; Chromatography, High Pressure Liquid; Chromatography, Liquid; Drug Stability; Humans; Mass Spectrometry; Reproducibility of Results; Sensitivity and Specificity; Thermolysin | 2005 |
Are there any better camptothecins than the ones we have?
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Drug Resistance, Neoplasm; Humans; Irinotecan; Pancreatic Neoplasms; Research; Topoisomerase I Inhibitors | 2003 |
Exatecan and gemcitabine: no better than gemcitabine only.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Survival Rate | 2006 |
Quantitative acid hydrolysis of DE-310, a macromolecular carrier system for the camptothecin analog DX-8951f.
Topics: Acids; Camptothecin; Chromatography, High Pressure Liquid; Drug Carriers; Drug Stability; Enzyme Inhibitors; Hydrolysis; Magnetic Resonance Spectroscopy; Molecular Structure; Prodrugs; Reproducibility of Results | 2007 |
Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Epirubicin; Etoposide; Follow-Up Studies; Humans; Ifosfamide; Infection Control; Kaplan-Meier Estimate; Melphalan; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Postoperative Care; Retrospective Studies; Risk; Salvage Therapy; Sarcoma, Ewing; Topotecan; Transplantation Conditioning; Transplantation, Autologous; Treatment Failure; Vincristine | 2007 |
Relationship between drug release of DE-310, macromolecular prodrug of DX-8951f, and cathepsins activity in several tumors.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cathepsins; Cell Line, Tumor; Chromatography, High Pressure Liquid; Enzyme Inhibitors; Humans; Hydrolysis; Liver; Mice; Neoplasm Transplantation; Neoplasms; Prodrugs; Tissue Distribution; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays | 2007 |
Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Humans; Injections, Intraventricular; Mammary Neoplasms, Experimental; Mice; Molecular Conformation; Structure-Activity Relationship; Trastuzumab | 2016 |
A HER2-Targeting Antibody-Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model.
Topics: Animals; Antibodies, Monoclonal, Humanized; B7-H1 Antigen; Breast Neoplasms; Camptothecin; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Disease Models, Animal; Female; Gene Expression Regulation, Neoplastic; Humans; Immunoconjugates; Mice; Programmed Cell Death 1 Receptor; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2018 |
U3-1402, a Novel HER3-Targeting Antibody-Drug Conjugate, for the Treatment of Colorectal Cancer.
Topics: Animals; Antibodies, Monoclonal, Humanized; Broadly Neutralizing Antibodies; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Female; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Immunoconjugates; Mice; Receptor, ErbB-3; Up-Regulation; Xenograft Model Antitumor Assays | 2019 |
A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization.
Topics: Animals; Antibodies, Monoclonal, Humanized; Apoptosis; Camptothecin; Cell Proliferation; Drug Delivery Systems; Gene Expression Regulation, Neoplastic; Humans; Immunoconjugates; Macaca fascicularis; Male; Mice; Mice, Inbred NOD; Mice, Nude; Neoplasms; Rats; Receptor, ErbB-3; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys.
Topics: Animals; Camptothecin; Cathepsin B; Drug Administration Schedule; Female; Immunoconjugates; Lung; Lung Diseases, Interstitial; Macaca fascicularis; Male; Receptor, ErbB-2; Time Factors; Trastuzumab | 2020 |
TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor.
Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Camptothecin; DNA; DNA Topoisomerases, Type I; Humans; Mice; Neoplasms; Nuclear Proteins; Protein Kinase Inhibitors; Topoisomerase I Inhibitors | 2022 |
Antigen-independent tumor targeting by CBX-12 (alphalex
Topics: Animals; Camptothecin; Cell Line, Tumor; Immunity; Immunotherapy; Neoplasms; Tumor Microenvironment | 2022 |
A Very Long-acting Exatecan and Its Synergism with DNA Damage Response Inhibitors.
Topics: Animals; Antineoplastic Agents; Camptothecin; DNA Damage; Humans; Mice; Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols | 2023 |